Exit

Health Condition

Type 2 Diabetes

About This Condition

Diabetes mellitus is an inability to metabolize carbohydrates resulting from inadequate insulin production, absence of insulin production, or impaired utilization of insulin. Other forms of diabetes (such as diabetes insipidus and gestational diabetes) are not included in this discussion.

There are several types of diabetes mellitus including type 1, type 2, and gestational diabetes, as well as diabetes insipidus, and a more recently recognized form of adult-onset diabetes called latent autoimmune diabetes in adults (LADA).1 This article concerns type 2 diabetes, which has also been called adult-onset diabetes or non-insulin-dependent diabetes. However, type 2 diabetes also may affect children and may also require treatment with insulin. With type 2 diabetes, the pancreas often makes enough insulin, particularly when a person is first diagnosed, but the body has trouble using it. Type 2 diabetes frequently responds well to natural therapies; however, if the condition is not well managed, the body may be unable to continue to make adequate insulin, requiring treatment with insulin. For many people with type 2 diabetes, lifestyle changes and/or oral glucose lowering medications are able to keep the condition well-managed.

People with diabetes cannot properly process glucose, the main sugar the body uses for energy. As a result, glucose stays in the blood, causing blood glucose to rise. At the same time, the cells of the body are starved for glucose, because without insulin, glucose cannot enter cells. People with diabetes are at increased risk for heart disease, atherosclerosis, cataracts, retinopathy, stroke, poor wound healing, infections, and damage to the kidneys and nerves. In addition, those with diabetes have a higher mortality rate if they also have high homocysteine levels.2 The risk of diabetes-related health complications can be decreased with proper blood sugar management and a healthy lifestyle.

Reducing Your Risk

To help keep you in top health, our experts recommend these steps:

  • Lose a little, win better health. Healthy weight is one of the keys to keeping type 2 diabetes at bay. If you carry extra pounds, losing just 5% to 10% of your body weight—that’s 10 to 20 pounds on a 200-pound person—may improve blood sugar control. Select Eating Right, above, for more on weight management.
  • Feast on fiber. Fiber is important for keeping blood sugar and insulin levels stable. If you don’t get enough from food, a fiber supplement may be a good addition to your diabetes prevention plan. Select Eating Right, above, for more healthy eating tips.
  • Consider the options. Even people who don’t have diabetes may benefit from medications to manage diabetes risk factors. If you fall into the “pre-diabetes” category, or the disease runs in your family, talk to your doctor about whether medications are right for you. Select Medicines, above, for more information.
  • Consider your heritage. This is especially important for Asian Americans, because there is evidence that this population is at an increased risk for diabetes at a relatively lower BMI than the general population. In the 2015 American Diabetes Association guidelines, the BMI cutoff point for recommending a diabetes screening for overweight or obese people was changed from 25 kg/m2 to 23 kg/m2 for Asian Americans, who have one or more additional risk factors for diabetes. This means screening in this population should begin even when a person’s BMI falls into what is considered the healthy BMI range for the general population.3
  • Mobilize your motivation. Consider a tool, such as a pedometer to up your game. For some people, tracking steps taken per day, or other get-fit activities, is a great motivator to reaching better health. Select Personal Care, above, for more ideas on tools for a healthier life.
  • Avoid prolonged sitting. All individuals, including those with diabetes, should limit the amount of sedentary time by breaking up extended periods of sitting (more than 90 min). This means frequent breaks while working at a desk, watching television, or engaging in other sedentary pursuits, such as reading or sewing.4 Stand up, stretch, move around, and shake out the kinks!
  • Quit smartly. If you smoke, talk to your health care provider about safe ways to help you quit. Although e-cigarettes have become popular in recent years, they should not be used as an alternative to smoking or to facilitate smoking cessation.4

Living With It

Our experts recommend the following top tips to support your blood sugar levels—and your life:

  • Become a mix master. Eating a mix of protein, fat, and fiber with each meal and snack is a great way to balance blood sugar. Add a small handful of nuts to your fruit, for example, for a mid-afternoon nosh. Eating Right, above, provides more great ideas for diabetes-friendly nutrition approaches.
  • Master your medications. If you take medicines to manage your diabetes, ask your doctor, nurse, or pharmacist for a complete explanation of how and when to take them, and whether they are safe to use with other medicines and supplements. Medicines, above, will give you an introduction to commonly prescribed diabetes medications.
  • Work with an expert. Nutrition therapy delivered by a registered dietitian (RD) is recommended for all people with type 2 diabetes; it should begin at diagnosis or at first referral for medical nutrition therapy (MNT), should be comprised of three to four encounters lasting 45–90 minutes, and should be completed within three to six months. At least one follow-up encounter is recommended annually to reinforce lifestyle changes and to evaluate and monitor outcomes that indicate the need for changes in MNT or medication(s); an RD should determine whether additional MNT sessions are needed.6
  • Track with accuracy. Finding the right tools to track your condition is important. Learn all you can about the features and costs of various glucose monitors. It may be worth a little more if you like extra features, such as an option to download your results to a computer. Select Personal Care, above, for more ideas on tools for a healthier life. Regular follow-up visits with a diabetes health care practitioner, including downloading and reviewing glucose monitoring results, is important.7
  • Spice it up. Fenugreek, a seed commonly used to flavor Indian and Asian dishes, may help prevent blood sugar spikes after meals. Select Vitamins, above, for the full scoop on supplements for diabetes support.

References

1. Gebel E. The Other Diabetes, LADA, or type 1.5. Diabetes Forecast 2010 May [cited 2015 Mar 14]. Available from URL: http://www.diabetesforecast.org/2010/may/the-other-diabetes-lada-or-type-1-5.html.

2. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation 2000;101:1506-11.

3. 2015 Position Statement on Classification and Diagnosis of Diabetes. American Diabetes Association [cited 2015 Feb 15]. Available from URL: http://care.diabetesjournals.org/content/38/Supplement_1/S8.full.

4. 2015 Position Statement on Foundations of Care: Education, Nutrition, Physical Activity, Smoking Cessation, Psychosocial Care, and Immunization. American Diabetes Association [cited 2015 Feb 16]. Available from URL: http://care.diabetesjournals.org/content/38/Supplement_1/S20.full.

5. Evert AB, Boucher JL, Cypress M, et al., American Diabetes Association. Nutrition Therapy Recommendations for the Management of Adults With Diabetes. Diabetes Care 2013. 36(11):3821-42.

6. Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association. American Diabetes Association [cited 2015 Feb 16]. Available from URL: http://care.diabetesjournals.org/content/37/7/2034.

7. Gomes M, Negrato C. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr 2014;6:80.

8. Garcia-Alcala H, Santos Vichido C, Islas Macedo S, et al. Treatment with alpha-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading. J Diabetes Res 2015;2015:189857.

9. Ziegler D, Low P, Litchy W, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011;34:2054–60.

10. Udupa A, Nahar P, Shah S, et al. A comparative study of effects of omega-3 Fatty acids, alpha lipoic Acid and vitamin e in type 2 diabetes mellitus. Ann Med Health Sci Res 2013;3:442–6.

11. Zhao L, Hu F. Alpha-Lipoic acid treatment of aged type 2 diabetes mellitus complicated with acute cerebral infarction. Eur Rev Med Pharmacol Sci 2014;18:3715–9.

12. Okanovic A, Prnjavorac B, Jusufovic E, Sejdinovic R. Alpha-lipoic acid reduces body weight and regulates triglycerides in obese patients with diabetes mellitus. Med Glas (Zenica) 2015;12:122–7.

13. Nebbioso M, Pranno F, Pescosolido N. Lipoic acid in animal models and clinical use in diabetic retinopathy. Expert Opin Pharmacother 2013;14:1829–38.

14. Gebka A, Serkies-Minuth E, Raczynska D. Effect of the administration of alpha-lipoic acid on contrast sensitivity in patients with type 1 and type 2 diabetes. Mediators Inflamm 2014;2014:131538.

15. Hong Y, Peng J, Cai X, et al. Clinical Efficacy of Alprostadil Combined with alpha-lipoic Acid in the Treatment of Elderly Patients with Diabetic Nephropathy. Open Med (Wars) 2017;12:323–7.

16. Mitkov M, Aleksandrova I, Orbetzova M. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv) 2013;55:55–63.

17. Hosseinzadeh P, Javanbakht M, Mostafavi S, et al. Brewer's Yeast Improves Glycemic Indices in Type 2 Diabetes Mellitus. Int J Prev Med 2013;4:1131–8.

18. Ngala R, Awe M, Nsiah P. The effects of plasma chromium on lipid profile, glucose metabolism and cardiovascular risk in type 2 diabetes mellitus. A case - control study. PLoS One 2018;13:e0197977.

19. Khosravi-Boroujeni H, Rostami A, Ravanshad S, Esmaillzadeh A. Favorable effects on metabolic risk factors with daily brewer's yeast in type 2 diabetic patients with hypercholesterolemia: a semi-experimental study. J Diabetes 2012;4:153–8.

20. Sharma S, Agrawal RP, Choudhary M, et al. Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes. J Trace Elem Med Biol 2011;25:149–53.

21. Bahijiri S, Mira S, Mufti A, Ajabnoor M. The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. Saudi Med J 2000;21:831–7.

22. Racek J, Sindberg C, Moesgaard S, et al. Effect of chromium-enriched yeast on fasting plasma glucose, glycated hemoglobin and serum lipid levels in patients with type 2 diabetes mellitus treated with insulin. Biol Trace Elem Res 2013;155:1–4.

23. Yanni A, Stamataki N, Konstantopoulos P, et al. Controlling type-2 diabetes by inclusion of Cr-enriched yeast bread in the daily dietary pattern: a randomized clinical trial. Eur J Nutr 2018;57:259–67.

24. Chen S, Jin X, Shan Z, et al. Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study. Nutrients 2017;9.

25. McIver D, Grizales A, Brownstein J, Goldfine A. Risk of Type 2 Diabetes Is Lower in US Adults Taking Chromium-Containing Supplements. J Nutr 2015;145:2675–82.

26. Ngala R, Awe M, Nsiah P. The effects of plasma chromium on lipid profile, glucose metabolism and cardiovascular risk in type 2 diabetes mellitus. A case - control study. PLoS One 2018;13:e0197977.

27. Rajendran K, Manikandan S, Nair L, et al. Serum Chromium Levels in Type 2 Diabetic Patients and Its Association with Glycaemic Control. J Clin Diagn Res 2015;9:Oc05–8.

28. Farrokhian A, Mahmoodian M, Bahmani F, et al. The Influences of Chromium Supplementation on Metabolic Status in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease. Biol Trace Elem Res 2019.

29. Huang H, Chen G, Dong Y, et al. Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: Results from a pooled analysis. Mol Nutr Food Res 2018;62.

30. Brownley K, Boettiger C, Young L, Cefalu W. Dietary chromium supplementation for targeted treatment of diabetes patients with comorbid depression and binge eating. Med Hypotheses 2015;85:45–8.

31. Koupy D, Kotolova H, Ruda Kucerova J. Effectiveness of phytotherapy in supportive treatment of type 2 diabetes mellitus II. Fenugreek (Trigonella foenum-graecum). Ceska Slov Farm 2015;64:67–71.

32. Kiss R, Szabo K, Gesztelyi R, et al. Insulin-Sensitizer Effects of Fenugreek Seeds in Parallel with Changes in Plasma MCH Levels in Healthy Volunteers. Int J Mol Sci 2018;19.

33. Ranade M, Mudgalkar N. A simple dietary addition of fenugreek seed leads to the reduction in blood glucose levels: A parallel group, randomized single-blind trial. Ayu 2017;38:24–7.

34. Gaddam A, Galla C, Thummisetti S, et al. Role of Fenugreek in the prevention of type 2 diabetes mellitus in prediabetes. J Diabetes Metab Disord 2015;14:74.

35. Verma N, Usman K, Patel N, et al. A multicenter clinical study to determine the efficacy of a novel fenugreek seed (Trigonella foenum-graecum) extract (Fenfuro) in patients with type 2 diabetes. Food Nutr Res /em> 2016;60:32382.

36. Neelakantan N, Narayanan M, de Souza R, van Dam R. Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: a meta-analysis of clinical trials. Nutr J 2014;13:7.

37. Weickert M, Pfeiffer A. Impact of Dietary Fiber Consumption on Insulin Resistance and the Prevention of Type 2 Diabetes. J Nutr 2018;148:7–12.

38. Davison K, Temple N. Cereal fiber, fruit fiber, and type 2 diabetes: Explaining the paradox. J Diabetes Complications 2018;32:240–5.

39. Wang Y, Duan Y, Zhu L, et al. Whole grain and cereal fiber intake and the risk of type 2 diabetes: a meta-analysis. Int J Mol Epidemiol Genet 2019;10:38–46.

40. Silva F, Kramer C, de Almeida J, et al. Fiber intake and glycemic control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials. Nutr Rev 2013;71:790–801.

41. Jovanovski E, Khayyat R, Zurbau A, et al. Should Viscous Fiber Supplements Be Considered in Diabetes Control? Results from a Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2019;42:755–66.

42. Gibb R, McRorie J, Jr., Russell D, et al. Psyllium fiber improves glycemic control proportional to loss of glycemic control: a meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus. Am J Clin Nutr 2015;102:1604–14.

43. He L, Zhao J, Huang Y, Li Y. The difference between oats and beta-glucan extract intake in the management of HbA1c, fasting glucose and insulin sensitivity: a meta-analysis of randomized controlled trials. Food Funct 2016;7:1413–28.

44. Dall'Alba V, Silva F, Antonio J, et al. Improvement of the metabolic syndrome profile by soluble fibre - guar gum - in patients with type 2 diabetes: a randomised clinical trial. Br J Nutr 2013;110:1601–10.

45. Liu F, Prabhakar M, Ju J, et al. Effect of inulin-type fructans on blood lipid profile and glucose level: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr 2017;71:9–20.

46. Tinelli C, Di Pino A, Ficulle E, et al. Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies. Front Nutr 2019;6:49.

47. Zhao J, Schooling C, Zhao J. The effects of folate supplementation on glucose metabolism and risk of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Ann Epidemiol 2018;28:249–57.e241.

48. Xu C, Wu Y, Liu G, et al. Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta-analysis. Diagn Pathol 2014;9:167.

49. Mao S, Xiang W, Huang S, Zhang A. Association between homocysteine status and the risk of nephropathy in type 2 diabetes mellitus. Clin Chim Acta 2014;431:206–10.

50. Sudchada P, Saokaew S, Sridetch S, et al. Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 2012;98:151–8.

51. Smolek M, Notaroberto N, Jaramillo A, Pradillo L. Intervention with vitamins in patients with nonproliferative diabetic retinopathy: a pilot study. Clin Ophthalmol 2013;7:1451–8.

52. Fonseca V, Lavery L, Thethi T, et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med 2013;126:141–9.

53. Jacobs A, Cheng D. Management of diabetic small-fiber neuropathy with combination L-methylfolate, methylcobalamin, and pyridoxal 5'-phosphate. Rev Neurol Dis 2011;8:39–47.

54. Walker M, Jr., Morris L, Cheng D. Improvement of cutaneous sensitivity in diabetic peripheral neuropathy with combination L-methylfolate, methylcobalamin, and pyridoxal 5'-phosphate. Rev Neurol Dis 2010;7:132–9.

55. Chearskul S, Sangurai S, Nitiyanant W, et al. Glycemic and lipid responses to glucomannan in Thais with type 2 diabetes mellitus. J Med Assoc Thai 2007;90:2150–7.

56. Yoshida M, Vanstone C, Parsons W, et al. Effect of plant sterols and glucomannan on lipids in individuals with and without type II diabetes. Eur J Clin Nutr 2006;60:529–37.

57. Chen H, Sheu W, Tai T, et al. Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects--a randomized double-blind trial. J Am Coll Nutr 2003;22:36–42.

58. Chen H, Nie Q, Hu J, et al. Glucomannans Alleviated the Progression of Diabetic Kidney Disease by Improving Kidney Metabolic Disturbance. Mol Nutr Food Res 2019;63:e1801008.

59. Ozcaliskan Ilkay H, Sahin H, Tanriverdi F, Samur G. Association Between Magnesium Status, Dietary Magnesium Intake, and Metabolic Control in Patients with Type 2 Diabetes Mellitus. J Am Coll Nutr 2019;38:31–9.

60. Hruby A, Guasch-Ferre M, Bhupathiraju S, et al. Magnesium Intake, Quality of Carbohydrates, and Risk of Type 2 Diabetes: Results From Three U.S. Cohorts. Diabetes Care 2017;40:1695–702.

61. Chen S, Jin X, Liu J, et al. Association of Plasma Magnesium with Prediabetes and Type 2 Diabetes Mellitus in Adults. Sci Rep 2017;7:12763.

62. Fang X, Han H, Li M, et al. Dose-Response Relationship between Dietary Magnesium Intake and Risk of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Regression Analysis of Prospective Cohort Studies. Nutrients 2016;8.

63. Kostov K. Effects of Magnesium Deficiency on Mechanisms of Insulin Resistance in Type 2 Diabetes: Focusing on the Processes of Insulin Secretion and Signaling. Int J Mol Sci 2019;20.

64. Barbagallo M, Dominguez L. Magnesium and type 2 diabetes. World J Diabetes 2015;6:1152–7.

65. Kumar P, Bhargava S, Agarwal P, et al. Association of serum magnesium with type 2 diabetes mellitus and diabetic retinopathy. J Family Med Prim Care 2019;8:1671–7.

66. Joy S, George T, Siddiqui K. Low magnesium level as an indicator of poor glycemic control in type 2 diabetic patients with complications. Diabetes Metab Syndr 2019;13:1303–7.

67. Zhang Q, Ji L, Zheng H, et al. Low serum phosphate and magnesium levels are associated with peripheral neuropathy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2018;146:1-7.

68. Gant C, Soedamah-Muthu S, Binnenmars S, et al. Higher Dietary Magnesium Intake and Higher Magnesium Status Are Associated with Lower Prevalence of Coronary Heart Disease in Patients with Type 2 Diabetes. Nutrients 2018;10.

69. Bherwani S, Jibhkate S, Saumya A, et al. Hypomagnesaemia: a modifiable risk factor of diabetic nephropathy. Horm Mol Biol Clin Investig 2017;29:79–84.

70. Dibaba D, Xun P, Song Y, et al. The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2017;106:921–9.

71. Verma H, Garg R. Effect of magnesium supplementation on type 2 diabetes associated cardiovascular risk factors: a systematic review and meta-analysis. J Hum Nutr Diet 2017;30:621–33.

72. ELDerawi W, Naser I, Taleb M, Abutair A. The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients. Nutrients 2018;11.

73. Talari H, Zakizade M, Soleimani A, et al. Effects of magnesium supplementation on carotid intima-media thickness and metabolic profiles in diabetic haemodialysis patients: a randomised, double-blind, placebo-controlled trial. Br J Nutr 2019;121:809–17.

74. Sadeghian M, Azadbakht L, Khalili N, et al. Oral Magnesium Supplementation Improved Lipid Profile but Increased Insulin Resistance in Patients with Diabetic Nephropathy: a Double-Blind Randomized Controlled Clinical Trial. Biol Trace Elem Res 2019.

75. He J, Zhang F, Han Y. Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: A meta-analysis of RCTs. Medicine (Baltimore) 2017;96:e9166.

76. Wang X, Juan Q, He Y, et al. Multiple effects of probiotics on different types of diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Pediatr Endocrinol Metab 2017;30:611–22.

77. Hu Y, Zhou F, Yuan Y, Xu Y. Effects of probiotics supplement in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. Med Clin (Barc) 2017;148:362–70.

78. Akbari V, Hendijani F. Effects of probiotic supplementation in patients with type 2 diabetes: systematic review and meta-analysis. Nutr Rev 2016;74:774–84.

79. Li C, Li X, Han H, et al. Effect of probiotics on metabolic profiles in type 2 diabetes mellitus: A meta-analysis of randomized, controlled trials. Medicine (Baltimore) 2016;95:e4088.

80. Tiderencel K, Hutcheon D, Ziegler J. Probiotics for the treatment of type 2 diabetes: A review of randomized controlled trials. Diabetes Metab Res Rev 2019:e3213.

81. Gibb R, McRorie J, Jr., Russell D, et al. Psyllium fiber improves glycemic control proportional to loss of glycemic control: a meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus. Am J Clin Nutr 2015;102:1604–14.

82. Huseini H, Kianbakht S, Hajiaghaee R, Dabaghian F. Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Planta Med 2012;78:311–6.

83. Choudhary M, Kochhar A, Sangha J. Hypoglycemic and hypolipidemic effect of Aloe vera L. in non-insulin dependent diabetics. J Food Sci Technol 2014;51:90–6.

84. De Souza L, Jenkins A, Jovanovski E, et al. Ethanol extraction preparation of American ginseng (Panax quinquefolius L) and Korean red ginseng (Panax ginseng C.A. Meyer): differential effects on postprandial insulinemia in healthy individuals. J Ethnopharmacol 2015;159:55–61.

85. Shishtar E, Sievenpiper J, Djedovic V, et al. The effect of ginseng (the genus panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. PLoS One 2014;9:e107391.

86. Gui Q, Xu Z, Xu K, Yang Y. The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis. Medicine (Baltimore) 2016;95:e2584.

87. Vuksan V, Xu Z, Jovanovski E, et al. Efficacy and safety of American ginseng (Panax quinquefolius L.) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial. Eur J Nutr 2019;58:1237–45.

88. Mucalo I, Jovanovski E, Rahelic D, et al. Effect of American ginseng (Panax quinquefolius L.) on arterial stiffness in subjects with type-2 diabetes and concomitant hypertension. J Ethnopharmacol 2013;150:148–53.

89. Mucalo I, Jovanovski E, Vuksan V, et al. American Ginseng Extract (Panax quinquefolius L.) Is Safe in Long-Term Use in Type 2 Diabetic Patients. Evid Based Complement Alternat Med 2014;2014:969168.

90. Gui Q, Xu Z, Xu K, Yang Y. The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis. Medicine (Baltimore) 2016;95:e2584.

91. Shishtar E, Sievenpiper J, Djedovic V, et al. The effect of ginseng (the genus panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. PLoS One 2014;9:e107391.

92. Oh M, Park S, Kim S, et al. Postprandial glucose-lowering effects of fermented red ginseng in subjects with impaired fasting glucose or type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. BMC Complement Altern Med 2014;14:237.

93. Zhou P, Xie W, He S, et al. Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis. Cells 2019;8.

94. Bai L, Gao J, Wei F, et al. Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes. Front Pharmacol 2018;9:423.

95. Bang H, Kwak JH, Ahn HY, et al. Korean red ginseng improves glucose control in subjects with impaired fasting glucose, impaired glucose tolerance, or newly diagnosed type 2 diabetes mellitus. J Med Food 2014;17:128–34.

96. Yoon J, Kang S, Vassy J, et al. Efficacy and safety of ginsam, a vinegar extract from Panax ginseng, in type 2 diabetic patients: Results of a double-blind, placebo-controlled study. J Diabetes Investig 2012;3:309–17.

97. Vuksan V, Sung M, Sievenpiper J, et al. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutr Metab Cardiovasc Dis 2008;18:46–56.

98. Guo H, Ling W. The update of anthocyanins on obesity and type 2 diabetes: experimental evidence and clinical perspectives. Rev Endocr Metab Disord 2015;16:1–13.

99. Rozanska D, Regulska-Ilow B. The significance of anthocyanins in the prevention and treatment of type 2 diabetes. Adv Clin Exp Med 2018;27:135–42.

100. Karcheva-Bahchevanska D, Lukova P, Nikolova M, et al. Effect of Extracts of Bilberries (Vaccinium myrtillus L.) on Amyloglucosidase and alpha-Glucosidase Activity. Folia Med (Plovdiv) 2017;59:197–202.

101. Guo X, Yang B, Tan J, et al. Associations of dietary intakes of anthocyanins and berry fruits with risk of type 2 diabetes mellitus: a systematic review and meta-analysis of prospective cohort studies. Eur J Clin Nutr 2016;70:1360–7.

102. Rocha D, Caldas A, da Silva B, et al. Effects of blueberry and cranberry consumption on type 2 diabetes glycemic control: A systematic review. Crit Rev Food Sci Nutr 2019;59:1816–28.

103. Burton-Freeman B, Brzezinski M, Park E, et al. A Selective Role of Dietary Anthocyanins and Flavan-3-ols in Reducing the Risk of Type 2 Diabetes Mellitus: A Review of Recent Evidence. Nutrients 2019;11.

104. Cao H, Ou J, Chen L, et al. Dietary polyphenols and type 2 diabetes: Human Study and Clinical Trial. Crit Rev Food Sci Nutr 2018:1-9.

105. Yang L, Ling W, Du Z, et al. Effects of Anthocyanins on Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr 2017;8:684–93.

106. de Mello V, Lankinen M, Lindstrom J, et al. Fasting serum hippuric acid is elevated after bilberry (Vaccinium myrtillus) consumption and associates with improvement of fasting glucose levels and insulin secretion in persons at high risk of developing type 2 diabetes. Mol Nutr Food Res 2017;61.

107. Hoggard N, Cruickshank M, Moar K, et al. A single supplement of a standardized bilberry (Vaccinium myrtillus L.) extract (36 % wet weight anthocyanins) modifies glycaemic response in individuals with type 2 diabetes controlled by diet and lifestyle. J Nutr Sci 2013;2:e22.

108. Ghosh D, Konishi T. Anthocyanins and anthocyanin-rich extracts: role in diabetes and eye function. Asia Pac J Clin Nutr 2007;16:200–8.

109. Maebashi M, Makino Y, Furukawa Y, et al. Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin dependent diabetes mellitus. J Clin Biochem Nutr 1993;14:211–8

110. Revilla-Monsalve C, Zendejas-Ruiz I, Islas-Andrade S, et al. Biotin supplementation reduces plasma triacylglycerol and VLDL in type 2 diabetic patients and in nondiabetic subjects with hypertriglyceridemia. Biomed Pharmacother 2006;60:182–5.

111. Koutsikos D, Agroyannis B, Tzanatos-Exarchou H. Biotin for diabetic peripheral neuropathy. Biomed Pharmacother 1990;44:511–4.

112. Singer G, Geohas J. The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial. Diabetes Technol Ther 2006;8:636–43.

113. Albarracin C, Fuqua B, Geohas J, et al. Combination of chromium and biotin improves coronary risk factors in hypercholesterolemic type 2 diabetes mellitus: a placebo-controlled, double-blind randomized clinical trial. J Cardiometab Syndr 2007;2:91–7.

114. Geohas J, Daly A, Juturu V, et al. Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Am J Med Sci 2007;333:145–53.

115. Albarracin C, Fuqua B, Evans J, Goldfine I. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev 2008;24:41–51.

116. Shivanagoudra S, Perera W, Perez J, et al. In vitro and in silico elucidation of antidiabetic and anti-inflammatory activities of bioactive compounds from Momordica charantia L. Bioorg Med Chem 2019;27:3097–109.

117. Yin R, Lee N, Hirpara H, Phung O. The effect of bitter melon (Mormordica charantia) in patients with diabetes mellitus: a systematic review and meta-analysis. Nutr Diabetes 2014;4:e145.

118. Ooi C, Yassin Z, Hamid T. Momordica charantia for type 2 diabetes mellitus. Cochrane Database Syst Rev 2012:Cd007845.

119. Peter E, Kasali F, Deyno S, et al. Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis. J Ethnopharmacol 2019;231:311–24.

120. Cortez-Navarrete M, Martínez-Abundis E, Perez-Rubio K, et al. Momordica charantia Administration Improves Insulin Secretion in Type 2 Diabetes Mellitus. J Med Food 2018;21:672–7.

121. Inayat U, Khan R, Khalil Ur R, Bashir M. Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients. Nutr J 2015;14:13.

122. Mang B, Wolters M, Schmitt B, et al. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur J Clin Invest 2006;36:340–4.

123. Crawford P. Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial. J Am Board Fam Med 2009;22:507–12.

124. Akilen R, Tsiami A, Devendra D, Robinson N. Glycated haemoglobin and blood pressure-lowering effect of cinnamon in multi-ethnic Type 2 diabetic patients in the UK: a randomized, placebo-controlled, double-blind clinical trial. Diabet Med 2010;27:1159–67.

125. Lu T, Sheng H, Wu J, et al. Cinnamon extract improves fasting blood glucose and glycosylated hemoglobin level in Chinese patients with type 2 diabetes. Nutr Res 2012;32:408–12.

126. Sahib A. Anti-diabetic and antioxidant effect of cinnamon in poorly controlled type-2 diabetic Iraqi patients: A randomized, placebo-controlled clinical trial. J Intercult Ethnopharmacol 2016;5:108–13.

127. Sengsuk C, Sanguanwong S, Tangvarasittichai O, Tangvarasittichai S. Effect of cinnamon supplementation on glucose, lipids levels, glomerular filtration rate, and blood pressure of subjects with type 2 diabetes mellitus. Diabetol Int 2016;7:124–32.

128. Talaei B, Amouzegar A, Sahranavard S, et al. Effects of Cinnamon Consumption on Glycemic Indicators, Advanced Glycation End Products, and Antioxidant Status in Type 2 Diabetic Patients. Nutrients 2017;9.

129. Deyno S, Eneyew K, Seyfe S, et al. Efficacy and safety of cinnamon in type 2 diabetes mellitus and pre-diabetes patients: A meta-analysis and meta-regression. Diabetes Res Clin Pract 2019;156:107815.

130. Namazi N, Khodamoradi K, Khamechi S, et al. The impact of cinnamon on anthropometric indices and glycemic status in patients with type 2 diabetes: A systematic review and meta-analysis of clinical trials. Complement Ther Med 2019;43:92–101.

131. Yen C, Chu Y, Lee B, et al. Effect of liquid ubiquinol supplementation on glucose, lipids and antioxidant capacity in type 2 diabetes patients: a double-blind, randomised, placebo-controlled trial. Br J Nutr 2018;120:57–63.

132. Raygan F, Rezavandi Z, Dadkhah Tehrani S, et al The effects of coenzyme Q10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress in patients with metabolic syndrome. Eur J Nutr 2016;55:2357–64.

133. Zahedi H, Eghtesadi S, Seifirad S, et al. Effects of CoQ10 Supplementation on Lipid Profiles and Glycemic Control in Patients with Type 2 Diabetes: a randomized, double blind, placebo-controlled trial. J Diabetes Metab Disord 2014;13:81.

134. Kolahdouz Mohammadi R, Hosseinzadeh-Attar M, Eshraghian M, et al. The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients. Minerva Gastroenterol Dietol 2013;59:231–6.

135. Mezawa M, Takemoto M, Onishi S, et al. The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study. Biofactors 2012;38:416–21.

136. Zhang S, Yang K, Zeng L, et al. Effectiveness of Coenzyme Q10 Supplementation for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Int J Endocrinol 2018;2018:6484839.

137. Huang H, Chi H, Liao D, Zou Y. Effects of coenzyme Q10 on cardiovascular and metabolic biomarkers in overweight and obese patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Metab Syndr Obes 2018;11:875–86.

138. Akbari Fakhrabadi M, Zeinali Ghotrom A, Mozaffari-Khosravi H, et al. Effect of Coenzyme Q10 on Oxidative Stress, Glycemic Control and Inflammation in Diabetic Neuropathy: A Double Blind Randomized Clinical Trial. Int J Vitam Nutr Res 2014;84:252–60.

139. Stohs S, Miller H, Kaats G. A review of the efficacy and safety of banaba (Lagerstroemia speciosa L.) and corosolic acid. Phytother Res 2012;26:317–24.

140. Judy W, Hari S, Stogsdill W, et al. Antidiabetic activity of a standardized extract (Glucosol) from Lagerstroemia speciosa leaves in Type II diabetics. A dose-dependence study. J Ethnopharmacol 2003;87:115–7.

141. Casanova E, Salvado J, Crescenti A, Gibert-Ramos A. Epigallocatechin Gallate Modulates Muscle Homeostasis in Type 2 Diabetes and Obesity by Targeting Energetic and Redox Pathways: A Narrative Review. Int J Mol Sci 2019;20.

142. Yang C, Zhang J, Zhang L, et al. Mechanisms of body weight reduction and metabolic syndrome alleviation by tea. Mol Nutr Food Res 2016;60:160–74.

143. Ferreira M, Silva D, de Morais A, et al. Therapeutic potential of green tea on risk factors for type 2 diabetes in obese adults - a review. Obes Rev 2016;17:1316–28.

144. Keske M, Ng H, Premilovac D, et al. Vascular and metabolic actions of the green tea polyphenol epigallocatechin gallate. Curr Med Chem 2015;22:59–69.

145. Quezada-Fernandez P, Trujillo-Quiros J, Pascoe-Gonzalez S, et al. Effect of green tea extract on arterial stiffness, lipid profile and sRAGE in patients with type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled trial. Int J Food Sci Nutr 2019:1–9.

146. Liu K, Zhou R, Wang B, et al. Effect of green tea on glucose control and insulin sensitivity: a meta-analysis of 17 randomized controlled trials. Am J Clin Nutr 2013;98:340–8.

147. Yu J, Song P, Perry R, et al. The Effectiveness of Green Tea or Green Tea Extract on Insulin Resistance and Glycemic Control in Type 2 Diabetes Mellitus: A Meta-Analysis. Diabetes Metab J 2017;41:251–62.

148. Younes M, Aggett P, Aguilar F, et al. Scientific opinion on the safety of green tea catechins. EFSA Journal 2018;16:e05239.

149. Pothuraju R, Sharma R, Chagalamarri J, et al. A systematic review of Gymnema sylvestre in obesity and diabetes management. J Sci Food Agric 2014;94:834–40.

150. Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram E. Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients. J Ethnopharmacol 1990;30:295–300.

151. Kumar S, Mani U, Mani I. An open label study on the supplementation of Gymnema sylvestre in type 2 diabetics. J Diet Suppl 2010;7:273–82.

152. Al-Romaiyan A, Liu B, Asare-Anane H, et al. A novel Gymnema sylvestre extract stimulates insulin secretion from human islets in vivo and in vitro. Phytother Res 2010;24:1370–6.

153. Li Y, Zheng M, Zhai X, et al. Effect of Gymnema sylvestre, Citrus colocynthis and Artemisia absinthum on blood glucose and lipid profile in diabetic human. Acta Pol Pharm 2015;72:981–5.

154. Ononamadu C, Alhassan A, Imam A, et al. In vitro and in vivo anti-diabetic and anti-oxidant activities of methanolic leaf extracts of Ocimum canum. Caspian J Intern Med 2019;10:162–75.

155. Nyarko A, Asare-Anane H, Ofosuhene M, et al. Aqueous extract of Ocimum canum decreases levels of fasting blood glucose and free radicals and increases antiatherogenic lipid levels in mice. Vascul Pharmacol 2002;39:273–9.

156. Nyarko A, Asare-Anane H, Ofosuhene M, Addy M. Extract of Ocimum canum lowers blood glucose and facilitates insulin release by isolated pancreatic beta-islet cells. Phytomedicine 2002;9:346–51.

157. Viseshakul D, Premvatana P, Chularojmontri V, et al. Improved glucose tolerance induced by long term dietary supplementation with hairy basal seeds (Ocimum canum Sim) in diabetics. J Med Assoc Thailand 1985;68:408–11.

158. Suanarunsawat T, Anantasomboon G, Piewbang C. Anti-diabetic and anti-oxidative activity of fixed oil extracted from Ocimum sanctum L. leaves in diabetic rats. Exp Ther Med 2016;11:832–40.

159. Husain I, Chander R, Saxena J, et al. Antidyslipidemic Effect of Ocimum sanctum Leaf Extract in Streptozotocin Induced Diabetic Rats. Indian J Clin Biochem 2015;30:72–7.

160. Muralikrishnan G, Pillai S, Shakeel F. Protective effects of Ocimum sanctum on lipid peroxidation and antioxidant status in streptozocin-induced diabetic rats. Nat Prod Res 2012;26:474–8.

161. Patil R, Patil R, Ahirwar B, Ahirwar D. Isolation and characterization of anti-diabetic component (bioactivity-guided fractionation) from Ocimum sanctum L. (Lamiaceae) aerial part. Asian Pac J Trop Med 2011;4:278–82.

162. Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. Int J Clin Pharmacol Ther 1996;34:406–9.

163. Satapathy S, Das N, Bandyopadhyay D, et al. Effect of Tulsi (Ocimum sanctum Linn.) Supplementation on Metabolic Parameters and Liver Enzymes in Young Overweight and Obese Subjects. Indian J Clin Biochem 2017;32:357–63.

164. Adeva-Andany M, Calvo-Castro I, Fernandez-Fernandez C, et al. Significance of l-carnitine for human health. IUBMB Life 2017;69:578–94.

165. Bene J, Hadzsiev K, Melegh B. Role of carnitine and its derivatives in the development and management of type 2 diabetes. Nutr Diabetes 2018;8:8.

166. Ramazani M, Qujeq D, Moazezi Z. Assessing the Levels of L-Carnitine and Total Antioxidant Capacity in Adults with Newly Diagnosed and Long-Standing Type 2 Diabetes. Can J Diabetes 2019;43:46-50.e41.

167. Poorabbas A, Fallah F, Bagdadchi J, et al. Determination of free L-carnitine levels in type II diabetic women with and without complications. Eur J Clin Nutr 2007;61:892–5.

168. Ringseis R, Keller J, Eder K. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. Eur J Nutr 2012;51:1–18.

169. Vidal-Casariego A, Burgos-Pelaez R, Martinez-Faedo C, et al. Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Exp Clin Endocrinol Diabetes 2013;121:234–8.

170. El-Sheikh H, El-Haggar S, Elbedewy T. Comparative study to evaluate the effect of l-carnitine plus glimepiride versus glimepiride alone on insulin resistance in type 2 diabetic patients. Diabetes Metab Syndr 2019;13:167–73.

171. Derosa G, Maffioli P, Ferrari I, et al. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J 2010;57:777–86.

172. Derosa G, Maffioli P, Salvadeo S, et al. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern Med 2010;49:1717–25.

173. Galvano F, Li Volti G, Malaguarnera M, et al. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother 2009;10:1875–82.

174. Molfino A, Cascino A, Conte C, et al. Caloric restriction and L-carnitine administration improves insulin sensitivity in patients with impaired glucose metabolism. JPEN J Parenter Enteral Nutr 2010;34:295–9.

175. Imbe A, Tanimoto K, Inaba Y, et al. Effects of L-carnitine supplementation on the quality of life in diabetic patients with muscle cramps. Endocr J 2018;65:521–6.

176. Ebrahimpour-Koujan S, Gargari B, Mobasseri M, et al. Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: A Triple-blinded randomized controlled clinical trial. Phytomedicine 2018;44:39–44.

177. Ebrahimpour Koujan S, Gargari B, Mobasseri M, et al. Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial. Phytomedicine 2015;22:290–6.

178. Huseini H, Larijani B, Heshmat R, et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 2006;20:1036–9.

179. Di Pierro F, Bellone I, Rapacioli G, Putignano P. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndr Obes 2015;8:89–96.

180. Di Pierro F, Putignano P, Villanova N, et al. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol 2013;5:167–74.

181. Ikechukwu O, Ifeanyi O. The Antidiabetic Effects of The Bioactive Flavonoid (Kaempferol-3-O-beta-D-6{P- Coumaroyl} Glucopyranoside) Isolated from Allium cepa.Recent Pat Antiinfect Drug Discov 2016;11:44–52.

182. Oboh G, Ademiluyi A, Agunloye O, et al. Inhibitory Effect of Garlic, Purple Onion, and White Onion on Key Enzymes Linked with Type 2 Diabetes and Hypertension. J Diet Suppl 2019;16:105–18.

183. Akash M, Rehman K, Chen S. Spice plant Allium cepa: dietary supplement for treatment of type 2 diabetes mellitus. Nutrition 2014;30:1128–37.

184. Gautam S, Pal S, Maurya R, Srivastava A. Ethanolic extract of Allium cepa stimulates glucose transporter typ 4-mediated glucose uptake by the activation of insulin signaling. Planta Med 2015;81:208–14.

185. Taj Eldin I, Ahmed E, Elwahab H. Preliminary Study of the Clinical Hypoglycemic Effects of Allium cepa (Red Onion) in Type 1 and Type 2 Diabetic Patients. Environ Health Insights 2010;4:71–7.

186. Tjokroprawiro A, Pikir BS, Budhiarta AA, et al. Metabolic effects of onion and green beans on diabetic patients. Tohoku J Exp Med 1983;141:671–6.

187. Kim H, Park K, Lee S, et al. Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus. Ann Nutr Metab 2012;60:1–5.

188. Kim J, Kim J, Kang M, et al Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study. Eur J Clin Nutr 2005;59:456–8.

189. Kang M, Kim J, Yoon S, et al. Pinitol from soybeans reduces postprandial blood glucose in patients with type 2 diabetes mellitus. J Med Food 2006;9:182–6.

190. Liu X, Zhou HJ, Rohdewald P. French maritime pine bark extract Pycnogenol dose-dependently lowers glucose in type 2 diabetic patients. Diabetes Care 2004;27:839 [letter].

191. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res 2008;28:315–20.

192. Liu X, Wei J, Tan F, et al. Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. Life Sci 2004;75:2505–13.

193. Cesarone M, Belcaro G, Rohdewald P, et al. Improvement of diabetic microangiopathy with pycnogenol: A prospective, controlled study. Angiology 2006;57:431–6.

194. Schonlau F, Rohdewald P. Pycnogenol for diabetic retinopathy. A review. Int Ophthalmol 2001;24:161–71.

195. Spadea L, Balestrazzi E. Treatment of vascular retinopathies with Pycnogenol. Phytother Res 2001;15:219–23.

196. Steigerwalt R, Belcaro G, Cesarone MR, et al. Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy. J Ocul Pharmacol Ther 2009;25:537–40.

197. Belcaro G, Cesarone M, Errichi B, et al. Diabetic ulcers: microcirculatory improvement and faster healing with pycnogenol. Clin Appl Thromb Hemost 2006;12:318–23.

198. Vinciguerra G, Belcaro G, Cesarone MR, et al. Cramps and muscular pain: prevention with pycnogenol in normal subjects, venous patients, athletes, claudicants and in diabetic microangiopathy. Angiology 2006;57:331–9.

199. Merigliano C, Mascolo E, Burla R, et al. The Relationship Between Vitamin B6, Diabetes and Cancer. Front Genet 2018;9:388.

200. Kim H, Kang Y, Lee J, et al. The Postprandial Anti-Hyperglycemic Effect of Pyridoxine and Its Derivatives Using In Vitro and In Vivo Animal Models. Nutrients 2018;10.

201. Ahn H, Min K, Cho Y. Assessment of vitamin B(6) status in Korean patients with newly diagnosed type 2 diabetes. Nutr Res Pract 2011;5:34–9.

202. McCann V, Davis R. Serum pyridoxal concentrations in patients with diabetic neuropathy. Aust N Z J Med 1978;8:259–61.

203. Nix W, Zirwes R, Bangert V, et al. Vitamin B status in patients with type 2 diabetes mellitus with and without incipient nephropathy. Diabetes Res Clin Pract 2015;107:157–65.

204. Walker M, Morris L, Cheng D. Improvement of cutaneous sensitivity in diabetic peripheral neuropathy with combination L-methylfolate, methylcobalamin, and pyridoxal 5'-phosphate. Rev Neurol Dis 2010;7:132–9.

205. Smolek M, Notaroberto N, Jaramillo A, Pradillo L. Intervention with vitamins in patients with nonproliferative diabetic retinopathy: a pilot study. Clin Ophthalmol 2013;7:1451–8.

206. Mason S, Rasmussen B, van Loon L, et al. Ascorbic acid supplementation improves postprandial glycaemic control and blood pressure in individuals with type 2 diabetes: Findings of a randomized cross-over trial. Diabetes Obes Metab 2019;21:674–82.

207. Ashor A, Werner A, Lara J, et al. Effects of vitamin C supplementation on glycaemic control: a systematic review and meta-analysis of randomised controlled trials. Eur J Clin Nutr 2017;71:1371–80.

208. Das U. Vitamin C for Type 2 Diabetes Mellitus and Hypertension. Arch Med Res 2019;50:11–4.

209. Franke S, Muller L, Santos M, et al. Vitamin C intake reduces the cytotoxicity associated with hyperglycemia in prediabetes and type 2 diabetes. Biomed Res Int 2013;2013:896536.

210. Rahimi-Madiseh M, Malekpour-Tehrani A, Bahmani M, Rafieian-Kopaei M. The research and development on the antioxidants in prevention of diabetic complications. Asian Pac J Trop Med 2016;9:825–31.

211. May J. Ascorbic acid repletion: A possible therapy for diabetic macular edema? Free Radic Biol Med 2016;94:47–54.

212. Kundu D, Mandal T, Nandi M, et al. Oxidative stress in diabetic patients with retinopathy. Ann Afr Med 2014;13:41–6.

213. Park S, Ghim W, Oh S, et al. Association of vitreous vitamin C depletion with diabetic macular ischemia in proliferative diabetic retinopathy. PLoS One 2019;14:e0218433.

214. Moshetova L, Vorob'eva I, Alekseev I, Mikhaleva L. Results of the use of antioxidant and angioprotective agents in type 2 diabetes patients with diabetic retinopathy and age-related macular degeneration. Vestn Oftalmol. 2015;131:34–44. [in Russian]

215. Cho J, Ahn S, Yim J, et al. Influence of Vitamin C and Maltose on the Accuracy of Three Models of Glucose Meters. Ann Lab Med 2016;36:271–4.

216. Grammatiki M, Karras S, Kotsa K. The role of vitamin D in the pathogenesis and treatment of diabetes mellitus: a narrative review. Hormones (Athens) 2019;18:37–48.

217. Leung P. The Potential Protective Action of Vitamin D in Hepatic Insulin Resistance and Pancreatic Islet Dysfunction in Type 2 Diabetes Mellitus. Nutrients 2016;8:147.

218. Sacerdote A, Dave P, Lokshin V, Bahtiyar G. Type 2 Diabetes Mellitus, Insulin Resistance, and Vitamin D. Curr Diab Rep 2019;19:101.

219. Rafiq S, Jeppesen P. Is Hypovitaminosis D Related to Incidence of Type 2 Diabetes and High Fasting Glucose Level in Healthy Subjects: A Systematic Review and Meta-Analysis of Observational Studies. Nutrients 2018;10.

220. Li X, Liu Y, Zheng Y, et al. The Effect of Vitamin D Supplementation on Glycemic Control in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis. Nutrients 2018;10.

221. Wu C, Qiu S, Zhu X, Li L. Vitamin D supplementation and glycemic control in type 2 diabetes patients: A systematic review and meta-analysis. Metabolism 2017;73:67–76.

222. Lee C, Iyer G, Liu Y, et al. The effect of vitamin D supplementation on glucose metabolism in type 2 diabetes mellitus: A systematic review and meta-analysis of intervention studies. J Diabetes Complications 2017;31:1115–26.

223. Mirhosseini N, Vatanparast H, Mazidi M, Kimball S. The Effect of Improved Serum 25-Hydroxyvitamin D Status on Glycemic Control in Diabetic Patients: A Meta-Analysis. J Clin Endocrinol Metab 2017;102:3097–110.

224. Alam U, Arul-Devah V, Javed S, Malik R. Vitamin D and Diabetic Complications: True or False Prophet? Diabetes Ther 2016;7:11–26.

225. Zhao T, Huang Q, Su Y, et al. Zinc and its regulators in pancreas. Inflammopharmacology 2019;27:453–64.

226. Naik S, Ramanand S, Ramanand J. A Medley Correlation of Serum Zinc with Glycemic Parameters in T2DM Patients. Indian J Endocrinol Metab 2019;23:188–92.

227. Ruz M, Carrasco F, Rojas P, et al. Nutritional Effects of Zinc on Metabolic Syndrome and Type 2 Diabetes: Mechanisms and Main Findings in Human Studies. Biol Trace Elem Res 2019;188:177–88.

228. Ranasinghe P, Wathurapatha W, Galappatthy P, et al. Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial. J Diabetes 2018;10:386–97.

229. Fernández-Cao J, Warthon-Medina M, H Moran V, et al. Zinc Intake and Status and Risk of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Nutrients 2019;11.

230. Khan M, Siddique K, Ashfaq F, et al. Effect of high-dose zinc supplementation with oral hypoglycemic agents on glycemic control and inflammation in type-2 diabetic nephropathy patients. J Nat Sci Biol Med 2013;4:336–40.

231. Hussain S, Khadim H, Khalaf B, et al. Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi Med J 2006;27:1483–8.

232. Kadhim H, Ismail S, Hussein K, et al. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. J Pineal Res 2006;41:189–93.

233. Udani J, Singh B, Singh V, et al. Effects of Acai (Euterpe oleracea Mart.) berry preparation on metabolic parameters in a healthy overweight population: a pilot study. Nutr J 2011;10:45.

234. de Bem G, Costa C, Santos I, et al. Antidiabetic effect of Euterpe oleracea Mart. (acai) extract and exercise training on high-fat diet and streptozotocin-induced diabetic rats: A positive interaction. PLoS One 2018;13:e0199207.

235. de Bem G, da Costa C, da Silva Cristino Cordeiro V, et al. Euterpe oleracea Mart. (acai) seed extract associated with exercise training reduces hepatic steatosis in type 2 diabetic male rats. J Nutr Biochem 2018;52:70–81.

236. Liu D, Gao H, Tang W, Nie S. Plant non-starch polysaccharides that inhibit key enzymes linked to type 2 diabetes mellitus. Ann N Y Acad Sci 2017;1401:28–36.

237. Tiwari A. Revisiting "Vegetables" to combat modern epidemic of imbalanced glucose homeostasis. Pharmacogn Mag 2014;10:S207–13.

238. Wang H, Liu T, Huang D. Starch hydrolase inhibitors from edible plants. Adv Food Nutr Res 2013;70:103–36.

239. Thompson S, Winham D, Hutchins A. Bean and rice meals reduce postprandial glycemic response in adults with type 2 diabetes: a cross-over study. Nutr J 2012;11:23.

240. Barrett M, Udani J. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control. Nutr J 2011;10:24.

241. Omran O. Histopathological study of evening primrose oil effects on experimental diabetic neuropathy. Ultrastruct Pathol 2012;36:222–7.

242. Kim D, Yoo T, Lee S, et al. Gamma linolenic acid exerts anti-inflammatory and anti-fibrotic effects in diabetic nephropathy. Yonsei Med J 2012;53:1165–75.

243. Head R, McLennan P, Raederstorff D, et al. Prevention of nerve conduction deficit in diabetic rats by polyunsaturated fatty acids. Am J Clin Nutr 2000;71:386s–92s.

244. Jamal G, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet Med 1990;7:319–23.

245. Dyer O. GMC accuses doctor of research fraud. BMJ 2003;326:616.

246. Telle-Hansen V, Gaundal L, Myhrstad M. Polyunsaturated Fatty Acids and Glycemic Control in Type 2 Diabetes. Nutrients 2019;11.

247. Abbott K, Burrows T, Thota R, et al. Do omega-3 PUFAs affect insulin resistance in a sex-specific manner? A systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2016;104:1470–84.

248. O'Mahoney L, Matu J, Price O, et al. Omega-3 polyunsaturated fatty acids favorably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. Cardiovasc Diabetol 2018;17:98.

249. Gao H, Geng T, Huang T, Zhao Q. Fish oil supplementation and insulin sensitivity: a systematic review and meta-analysis. Lipids Health Dis 2017;16:131.

250. He M, Shi B. Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell Biosci 2017;7:54.

251. Colantonio A, Werner S, Brown M. The Effects of Prebiotics and Substances with Prebiotic Properties on Metabolic and Inflammatory Biomarkers in Individuals with Type 2 Diabetes Mellitus: A Systematic Review. J Acad Nutr Diet 2019.

252. Mahboobi S, Rahimi F, Jafarnejad S. Effects of Prebiotic and Synbiotic Supplementation on Glycaemia and Lipid Profile in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Adv Pharm Bull 2018;8:565–74.

253. Kudolo G, Wang W, Javors M, Blodgett J. The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study. Clin Nutr 2006;25:606–16.

254. Aziz T, Hussain S, Mahwi T, et al. The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial. Drug Des Devel Ther 2018;12:735–42.

255. Lu J, He H. Clinical observation of Gingko biloba extract injection in treating early diabetic nephropathy. Chin J Integr Med 2005;11:226–8. [in Chinese]

256. Huang S, Jeng C, Kao S, et al. Improved haemorrheological properties by Ginkgo biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy. Clin Nutr 2004;23:615–21.

257. Zhao Y, Yu J, Liu J, An X. The Role of Liuwei Dihuang Pills and Ginkgo Leaf Tablets in Treating Diabetic Complications. Evid Based Complement Alternat Med 2016;2016:7931314.

258. da Silva G, Zanoni J, Buttow N. Neuroprotective action of Ginkgo biloba on the enteric nervous system of diabetic rats. World J Gastroenterol 2011;17:898–905.

259. Taliyan R, Sharma P. Protective effect and potential mechanism of Ginkgo biloba extract EGb 761 on STZ-induced neuropathic pain in rats. Phytother Res 2012;26:1823–9.

260. Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010;59:285-92

261. Reis C, Dorea J, da Costa T. Effects of coffee consumption on glucose metabolism: A systematic review of clinical trials. J Tradit Complement Med 2019;9:184–91.

262. Rebelo I, Casal S. Coffee: A Dietary Intervention on Type 2 Diabetes? Curr Med Chem 2017;24:376–83.

263. Tunnicliffe J, Shearer J. Coffee, glucose homeostasis, and insulin resistance: physiological mechanisms and mediators. Appl Physiol Nutr Metab 2008;33:1290–300.

264. Henry-Vitrac C, Ibarra A, Roller M. Contribution of chlorogenic acids to the inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized decaffeinated green coffee extract. J Agric Food Chem 2010;58:4141–4.

265. Ho L, Varghese M, Wang J, et al. Dietary supplementation with decaffeinated green coffee improves diet-induced insulin resistance and brain energy metabolism in mice. Nutr Neurosci 2012;15:37–45.

266. Thom E. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people J Int Med Res 2007;35:900–8.

267. Giacoman-Martinez A, Alarcon-Aguilar FJ Zamilpa A, et al. Triterpenoids from Hibiscus sabdariffa L. with PPARdelta/gamma Dual Agonist Action: In Vivo, In Vitro and In Silico Studies. Planta Med 2019;85:412–23.

268. Huang C, Wang C, Yang Y, et al. Hibiscus sabdariffa polyphenols prevent palmitate-induced renal epithelial mesenchymal transition by alleviating dipeptidyl peptidase-4-mediated insulin resistance. Food Funct 2016;7:475–82.

269. Peng C, Yang Y, Chan K, et al. Hibiscus sabdariffa polyphenols alleviate insulin resistance and renal epithelial to mesenchymal transition: a novel action mechanism mediated by type 4 dipeptidyl peptidase. J Agric Food Chem 2014;62:9736–43.

270. Ademiluyi A, Oboh G. Aqueous extracts of Roselle (Hibiscus sabdariffa Linn.) varieties inhibit alpha-amylase and alpha-glucosidase activities in vitro. J Med Food 2013;16:88–93.

271. Peng C, Chyau C, Chan K, et al. Hibiscus sabdariffa polyphenolic extract inhibits hyperglycemia, hyperlipidemia, and glycation-oxidative stress while improving insulin resistance. J Agric Food Chem 2011;59:9901–9.

272. Mozaffari-Khosravi H, Jalali-Khanabadi B, Afkhami-Ardekani M, Fatehi F. Effects of sour tea (Hibiscus sabdariffa) on lipid profile and lipoproteins in patients with type II diabetes. J Altern Complement Med 2009;15:899–903.

273. Mozaffari-Khosravi H, Ahadi Z, Barzegar K. The effect of green tea and sour tea on blood pressure of patients with type 2 diabetes: a randomized clinical trial. J Diet Suppl 2013;10:105–15.

274. Mozaffari-Khosravi H, Jalali-Khanabadi B, Afkhami-Ardekani M, et al. The effects of sour tea (Hibiscus sabdariffa) on hypertension in patients with type II diabetes. J Hum Hypertens 2009;23:48–54.

275. Croze M, Soulage C. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 2013;95:1811–27.

276. Chukwuma C, Ibrahim M, Islam M. Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: a dual approach study. J Physiol Biochem 2016;72:791–801.

277. Gao Y, Zhang M, Wang T, et al. Hypoglycemic effect of D-chiro-inositol in type 2 diabetes mellitus rats through the PI3K/Akt signaling pathway. Mol Cell Endocrinol 2016;433:26–34.

278. Pintaudi B, Di Vieste G, Bonomo M. The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes. Int J Endocrinol 2016;2016:9132052.

279. Unfer V, Nestler J, Kamenov Z, et al. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. Int J Endocrinol 2016;2016:1849162.

280. Genazzani A. Inositol as putative integrative treatment for PCOS. Reprod Biomed Online 2016;33:770–80.

281. Li L, Yang X. The Essential Element Manganese, Oxidative Stress, and Metabolic Diseases: Links and Interactions. Oxid Med Cell Longev 2018;2018:7580707.

282. Shan Z, Chen S, Sun T, et al. U-Shaped Association between Plasma Manganese Levels and Type 2 Diabetes. Environ Health Perspect 2016;124:1876–81.

283. Burlet E, Jain S. Manganese supplementation increases adiponectin and lowers ICAM-1 and creatinine blood levels in Zucker type 2 diabetic rats, and downregulates ICAM-1 by upregulating adiponectin multimerization protein (DsbA-L) in endothelial cells. Mol Cell Biochem 2017;429:1–10.

284. Burlet E, Jain S. Manganese supplementation reduces high glucose-induced monocyte adhesion to endothelial cells and endothelial dysfunction in Zucker diabetic fatty rats. J Biol Chem 2013;288:6409–16.

285. Eckel R, Hanson A, Chen A, et al. Dietary substitution of medium-chain triglycerides improves insulin-mediated glucose metabolism in NIDDM subjects. Diabetes 1992;41:641–7.

286. Yost T, Erskine J, Gregg T, et al. Dietary substitution of medium chain triglycerides in subjects with non-insulin-dependent diabetes mellitus in an ambulatory setting: impact on glycemic control and insulin-mediated glucose metabolism. J Am Coll Nutr 1994;13:615–22.

287. Han J, Deng B, Sun J, et al. Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free-living type 2 diabetic Chinese subjects. Metabolism 2007;56:985–91.

288. Aldawsari H, Hanafy A, Labib G, Badr J. Antihyperglycemic activities of extracts of the mistletoes Plicosepalus acaciae and P. curviflorus in comparison to their solid lipid nanoparticle suspension formulations. Z Naturforsch C 2014;69:391–8.

289. Abdallah H, Farag M, Abdel-Naim A, et al. Mechanistic Evidence of Viscum schimperi (Viscaceae) Antihyperglycemic Activity: From a Bioactivity-guided Approach to Comprehensive Metabolite Profiling. Phytother Res 2015;29:1737–43.

290. Ko B, Kang S, Moon B, et al. A 70% Ethanol Extract of Mistletoe Rich in Betulin, Betulinic Acid, and Oleanolic Acid Potentiated beta-Cell Function and Mass and Enhanced Hepatic Insulin Sensitivity. Evid Based Complement Alternat Med 2016;2016:7836823.

291. Tang Y, Choi E, Han W, et al. Moringa oleifera from Cambodia Ameliorates Oxidative Stress, Hyperglycemia, and Kidney Dysfunction in Type 2 Diabetic Mice. J Med Food 2017;20:502–10.

292. Waterman C, Rojas-Silva P, Tumer T, et al. Isothiocyanate-rich Moringa oleifera extract reduces weight gain, insulin resistance, and hepatic gluconeogenesis in mice. Mol Nutr Food Res 2015;59:1013–24.

293. Azad S, Ansari P, Azam S, et al. Anti-hyperglycaemic activity of Moringa oleifera is partly mediated by carbohydrase inhibition and glucose-fibre binding. Biosci Rep 2017;37.

294. Khan W, Parveen R, Chester K, et al. Hypoglycemic Potential of Aqueous Extract of Moringa oleifera Leaf and In Vivo GC-MS Metabolomics. Front Pharmacol 2017;8:577.

295. Anthanont P, Lumlerdkij N, Akarasereenont P, et al. Moringa Oleifera Leaf Increases Insulin Secretion after Single Dose Administration: A Preliminary Study in Healthy Subjects. J Med Assoc Thai 2016;99:308–13.

296. Taweerutchana R, Lumlerdkij N, Vannasaeng S, et al. Effect of Moringa oleifera Leaf Capsules on Glycemic Control in Therapy-Naive Type 2 Diabetes Patients: A Randomized Placebo Controlled Study. Evid Based Complement Alternat Med 2017;2017:6581390.

297. Wainstein J, Ganz T, Boaz M, et al. Olive leaf extract as a hypoglycemic agent in both human diabetic subjects and in rats. J Med Food 2012;15:605–10.

298. Florentin M, Liberopoulos E, Elisaf M, Tsimihodimos V. No effect of fenugreek, bergamot and olive leaf extract on glucose homeostasis in patients with prediabetes: a randomized double-blind placebo-controlled study. Arch Med Sci Atheroscler Dis 2019;4:e162-e166.

299. Araki R, Fujie K, Yuine N, et al. Olive leaf tea is beneficial for lipid metabolism in adults with prediabetes: an exploratory randomized controlled trial. Nutr Res 2019;67:60–6.

300. de Bock M, Derraik J, Brennan C, et al. Olive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo-controlled, crossover trial. PLoS One 2013;8:e57622.

301. Yao Z, Gu Y, Zhang Q, et al. Estimated daily quercetin intake and association with the prevalence of type 2 diabetes mellitus in Chinese adults. Eur J Nutr 2019;58:819–30.

302. Chen S, Jiang H, Wu X, Fang J. Therapeutic Effects of Quercetin on Inflammation, Obesity, and Type 2 Diabetes. Mediators Inflamm 2016;2016:9340637.

303. Peng J, Li Q, Li K, et al. Quercetin Improves Glucose and Lipid Metabolism of Diabetic Rats: Involvement of Akt Signaling and SIRT1. J Diabetes Res 2017;2017:3417306.

304. Gaballah H, Zakaria S, Mwafy S, et al. Mechanistic insights into the effects of quercetin and/or GLP-1 analogue liraglutide on high-fat diet/streptozotocin-induced type 2 diabetes in rats. Biomed Pharmacother 2017;92:331–9.

305. Valensi P, Le Devehat C, Richard J, et al. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications 2005;19:247–53.

306. Yang Z, Wu F, He Y, et al. A novel PTP1B inhibitor extracted from Ganoderma lucidum ameliorates insulin resistance by regulating IRS1-GLUT4 cascades in the insulin signaling pathway. Food Funct 2018;9:397–406.

307. Yang Z, Chen C, Zhao J, et al. Hypoglycemic mechanism of a novel proteoglycan, extracted from Ganoderma lucidum, in hepatocytes. Eur J Pharmacol 2018;820:77–85.

308. Xiao C, Wu Q, Xie Y, et al. Hypoglycemic mechanisms of Ganoderma lucidum polysaccharides F31 in db/db mice via RNA-seq and iTRAQ. Food Funct 2018;9:6495–507.

309. Wang F, Zhou Z, Ren X, et al. Effect of Ganoderma lucidum spores intervention on glucose and lipid metabolism gene expression profiles in type 2 diabetic rats. Lipids Health Dis 2015;14:49.

310. Klupp N, Kiat H, Bensoussan A, et al. A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Sci Rep 2016;6:29540.

311. Ribeiro R, Bonfleur M, Batista T, et al. Regulation of glucose and lipid metabolism by the pancreatic and extra-pancreatic actions of taurine. Amino Acids 2018;50:1511–24.

312. Sak D, Erdenen F, Muderrisoglu C, et al. The Relationship between Plasma Taurine Levels and Diabetic Complications in Patients with Type 2 Diabetes Mellitus. Biomolecules 2019;9.

313. Sarkar P, Basak P, Ghosh S, et al. Prophylactic role of taurine and its derivatives against diabetes mellitus and its related complications. Food Chem Toxicol 2017;110:109–21.

314. Zheng Y, Ceglarek U, Huang T, et al. Plasma Taurine, Diabetes Genetic Predisposition, and Changes of Insulin Sensitivity in Response to Weight-Loss Diets. J Clin Endocrinol Metab 2016;101:3820–6.

315. Cohen N, Halberstam M, Shlimovich P, et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1995;95:2501–9.

316. Boden G, Chen X, Ruiz J, et al. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin dependent diabetes mellitus. Metabolism 1996;45:1130–5.

317. Cusi K, Cukier S, DeFronzo R, et al. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 2001;86:1410–7.

318. Halberstam M, Cohen N, Schlimovich P, et al. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 1996;45:659–66.

319. Goldfine A, Patti M, Zuberi L, et al. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism 2000;49:400–10.

320. Thompson K, Lichter J, LeBel C, et al. Vanadium treatment of type 2 diabetes: a view to the future. J Inorg Biochem 2009;103:554–8.

321. Linder K, Willmann C, Kantartzis K, et al. Dietary Niacin Intake Predicts the Decrease of Liver Fat Content During a Lifestyle Intervention. Sci Rep 2019;9:1303.

322. Collins P, Sattar N. Glycaemic Effects of Non-statin Lipid-Lowering Therapies. Curr Cardiol Rep 2016;18:133.

323. Fangmann D, Theismann E, Turk K, et al. Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans. Diabetes Care 2018;41:398–405.

324. Klein G, Stefanuto A, Boaventura B, et al. Mate tea (Ilex paraguariensis) improves glycemic and lipid profiles of type 2 diabetes and pre-diabetes individuals: a pilot study. J Am Coll Nutr 2011;30:320–32.

325. Chen C, Liu J, Sun M, et al. Acupuncture for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract 2019;36:100–12.

326. Firouzjaei A, Li G, Wang N, et al. Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. Nutr Diabetes 2016;6:e209.

327. Ahn A, Bennani T, Freeman R, et al. Two styles of acupuncture for treating painful diabetic neuropathy—a pilot randomised control trial. Acupunct Med 2007;25:11–7.

328. Bailey A, Wingard D, Allison M, et al. Acupuncture Treatment of Diabetic Peripheral Neuropathy in an American Indian Community. J Acupunct Meridian Stud 2017;10:90–5.

329. Davison K, Temple N. Cereal fiber, fruit fiber, and type 2 diabetes: Explaining the paradox. J Diabetes Complications 2018;32:240–5.

330. Wang Y, Duan Y, Zhu L, et al. Whole grain and cereal fiber intake and the risk of type 2 diabetes: a meta-analysis. Int J Mol Epidemiol Genet 2019;10:38–46.

331. McRae M. Dietary Fiber Intake and Type 2 Diabetes Mellitus: An Umbrella Review of Meta-analyses. J Chiropr Med 2018;17:44–53.

332. Li X, Cai X, Ma X, et al. Short- and Long-Term Effects of Wholegrain Oat Intake on Weight Management and Glucolipid Metabolism in Overweight Type-2 Diabetics: A Randomized Control Trial. Nutrients 2016;8.

333. Jung C, Choi K. Impact of High-Carbohydrate Diet on Metabolic Parameters in Patients with Type 2 Diabetes. Nutrients 2017;9.

334. Ajala O, English P, Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr 2013;97:505–16.

335. Tosti V, Bertozzi B, Fontana L. Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms. J Gerontol A Biol Sci Med Sci 2018;73:318–26.

336. Guasch-Ferre M, Merino J, Sun Q, et al. Dietary Polyphenols, Mediterranean Diet, Prediabetes, and Type 2 Diabetes: A Narrative Review of the Evidence. Oxid Med Cell Longev 2017;2017:6723931.

337. Esposito K, Maiorino M, Bellastella G, et al A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ Open 2015;5:e008222.

338. Billingsley H, Carbone S. The antioxidant potential of the Mediterranean diet in patients at high cardiovascular risk: an in-depth review of the PREDIMED. Nutr Diabetes 2018;8:13.

339. Evert A, Dennison M, Gardner C, et al. Nutrition Therapy for Adults with Diabetes or Prediabetes: A Consensus Report. Diabetes Care 2019;42:731–54.

340. Powers M, Bardsley J, Cypress M, et al. Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Clin Diabetes 2016;34:70–80.

341. Namazi N, Brett N, Bellissimo N, et al. The association between types of seafood intake and the risk of type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Health Promot Perspect 2019;9:164–73.

342. Sarmento R, Antonio J, de Miranda I, et al. Eating Patterns and Health Outcomes in Patients With Type 2 Diabetes. J Endocr Soc 2018;2:42–52.

343. Wallin A, Orsini N, Forouhi N, Wolk A. Fish consumption in relation to myocardial infarction, stroke and mortality among women and men with type 2 diabetes: A prospective cohort study. Clin Nutr 2018;37:590–6.

344. Chua J, Chia A, Chee M, et al. The relationship of dietary fish intake to diabetic retinopathy and retinal vascular caliber in patients with type 2 diabetes. Sci Rep 2018;8:730.

345. Kim H, Park S, Yang H, et al. Association between fish and shellfish, and omega-3 PUFAs intake and CVD risk factors in middle-aged female patients with type 2 diabetes. Nutr Res Pract 2015;9:496–502.

346. Kondo K, Morino K, Nishio Y, et al. A fish-based diet intervention improves endothelial function in postmenopausal women with type 2 diabetes mellitus: a randomized crossover trial. Metabolism 2014;63:930–40.

347. Alkhatib A, Tsang C, Tuomilehto J. Olive Oil Nutraceuticals in the Prevention and Management of Diabetes: From Molecules to Lifestyle. Int J Mol Sci 2018;19.

348. Schwingshackl L, Lampousi A, Portillo M, et al. Olive oil in the prevention and management of type 2 diabetes mellitus: a systematic review and meta-analysis of cohort studies and intervention trials. Nutr Diabetes 2017;7:e262.

349. Foscolou A, Critselis E, Panagiotakos D. Olive oil consumption and human health: A narrative review. Maturitas 2018;118:60–6.

350. Yubero-Serrano E, Lopez-Moreno J, Gomez-Delgado F, Lopez-Miranda J. Extra virgin olive oil: More than a healthy fat. Eur J Clin Nutr 2019;72:8–17.

351. Visioli F, Franco M, Toledo E, et al. Olive oil and prevention of chronic diseases: Summary of an International conference. Nutr Metab Cardiovasc Dis 2018;28:649–56.

352. Evert A, Dennison M, Gardner C, et al. Nutrition Therapy for Adults with Diabetes or Prediabetes: A Consensus Report. Diabetes Care 2019;42:731–54.

353. Added Sugars. American Heart Association [updated 2018 Apr 17]. Available from URL: https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/sugar/added-sugars.

354. Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med 2015;13:53.

355. van Werkhoven C, Huijts S. Vaccines to Prevent Pneumococcal Community-Acquired Pneumonia. Clin Chest Med 2018;39:733–52.

356. Meex R, Blaak E, van Loon L. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. Obes Rev 2019;20:1205–17.

357. Longo M, Zatterale F, Naderi J, et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci 2019;20.

358. Grams J, Garvey W. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. Curr Obes Rep 2015;4:287–302.

359. Luan X, Tian X, Zhang H, et al. Exercise as a prescription for patients with various diseases. J Sport Health Sci 2019;8:422–41.

360. Turner G, Quigg S, Davoren P, et al. Resources to Guide Exercise Specialists Managing Adults with Diabetes. Sports Med Open 2019;5:20.

361. Delevatti R, Bracht C, Lisboa S, et al. The Role of Aerobic Training Variables Progression on Glycemic Control of Patients with Type 2 Diabetes: a Systematic Review with Meta-analysis. Sports Med Open 2019;5:22.

362. Bailey D, Hewson D, Champion R, Sayegh S. Sitting Time and Risk of Cardiovascular Disease and Diabetes: A Systematic Review and Meta-Analysis. Am J Prev Med 2019;57:408–16.

363. Loh R, Stamatakis E, Folkerts D, et al. Effects of Interrupting Prolonged Sitting with Physical Activity Breaks on Blood Glucose, Insulin and Triacylglycerol Measures: A Systematic Review and Meta-analysis. Sports Med 2019.

364. Li X, Yu F, Zhou Y, He J. Association between alcohol consumption and the risk of incident type 2 diabetes: a systematic review and dose-response meta-analysis. Am J Clin Nutr 2016;103:818–29.

365. Knott C, Bell S, Britton A. Alcohol Consumption and the Risk of Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of More Than 1.9 Million Individuals From 38 Observational Studies. Diabetes Care 2015;38:1804–12.

366. Hirst J, Aronson J, Feakins B, et al. Short- and medium-term effects of light to moderate alcohol intake on glycaemic control in diabetes mellitus: a systematic review and meta-analysis of randomized trials. Diabet Med 2017;34:604–11.

367. Gepner Y, Golan R, Harman-Boehm I, et al. Effects of Initiating Moderate Alcohol Intake on Cardiometabolic Risk in Adults With Type 2 Diabetes: A 2-Year Randomized, Controlled Trial. Ann Intern Med 2015;163:569–79.

368. Golan R, Shai I, Gepner Y, et al. Effect of wine on carotid atherosclerosis in type 2 diabetes: a 2-year randomized controlled trial. Eur J Clin Nutr 2018;72:871–8.

369. O'Keefe E, DiNicolantonio J, O'Keefe J, Lavie C. Alcohol and CV Health: Jekyll and Hyde J-Curves. Prog Cardiovasc Dis 2018;61:68–75.

370. Tourkmani A, Alharbi T, Rsheed A, et al. Hypoglycemia in Type 2 Diabetes Mellitus patients: A review article. Diabetes Metab Syndr 2018;12:791–4.

371. Ahren B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155–63.

372. Zhu P, Pan X, Sheng L, et al. Cigarette Smoking, Diabetes, and Diabetes Complications: Call for Urgent Action. Curr Diab Rep 2017;17:78.

373. Sliwinska-Mosson M, Milnerowicz H. The impact of smoking on the development of diabetes and its complications. Diab Vasc Dis Res 2017;14:265–76.

374. Worku D, Worku E. A narrative review evaluating the safety and efficacy of e-cigarettes as a newly marketed smoking cessation tool. SAGE Open Med 2019;7:2050312119871405.

375. Machry R, Rados D, Gregorio G, Rodrigues T. Self-monitoring blood glucose improves glycemic control in type 2 diabetes without intensive treatment: A systematic review and meta-analysis. Diabetes Res Clin Pract 2018;142:173–87.

376. Malanda U, Welschen L, Riphagen I, et al. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev 2012;1:Cd005060.

377. Wood A, O'Neal D, Furler J, Ekinci E. Continuous glucose monitoring: a review of the evidence, opportunities for future use and ongoing challenges. Intern Med J 2018;48:499–508.

378. Carlson A, Mullen D, Bergenstal R. Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes. Diabetes Technol Ther 2017;19:S4–11.

Copyright © 2019 Healthnotes, Inc. All rights reserved. www.healthnotes.com

Learn more about Healthnotes, the company.

The information presented by Healthnotes is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. Self-treatment is not recommended for life-threatening conditions that require medical treatment under a doctor's care. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2019.